Cargando…

Microvascular C5b-9 deposition in non-lesional skin in patients with SLE and its correlation with active lupus nephritis: a prospective observational study

OBJECTIVE: Tissue damage in lupus nephritis (LN) is mediated by activation of the classical complement pathway. Complement-mediated upregulation of endothelial cell adhesion molecules is seen in dermal blood vessels of non-lesional skin of patients with active lupus. In diseases with systemic comple...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anderson, Meghan, Magro, Cynthia, Belmont, H Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Lupus Nephritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603335/ https://www.ncbi.nlm.nih.gov/pubmed/37879755 http://dx.doi.org/10.1136/lupus-2023-000996

Ejemplares similares

Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis
por: Boedigheimer, Michael J, et al.
Publicado: (2017)

Serum albumin at 1 year predicts long-term renal outcome in lupus nephritis
por: Domingues, Vinicius, et al.
Publicado: (2018)

Standardised incidence ratios (SIRs) for cancer after renal transplant in systemic lupus erythematosus (SLE) and non-SLE recipients
por: Ramsey-Goldman, Rosalind, et al.
Publicado: (2016)

Value of repeat biopsy in lupus nephritis flares
por: Greloni, G, et al.
Publicado: (2014)

Characteristics and renal survival of patients with lupus nephritis with glomerular immunoglobulin G(4) deposition: a single-centre retrospective analysis
por: Jiang, Xue, et al.
Publicado: (2022)

Role of early repeated renal biopsies in lupus nephritis
por: Zickert, A, et al.
Publicado: (2014)

Interferon (IFN)-λ is a potential mediator in lupus nephritis
por: Zickert, Agneta, et al.
Publicado: (2016)

Causes and predictors of mortality in biopsy-proven lupus nephritis: the Sarawak experience
por: Teh, Cheng Lay, et al.
Publicado: (2018)

Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis
por: Gomez Mendez, Liliana Michelle, et al.
Publicado: (2019)

Immune gene expression and functional networks in distinct lupus nephritis classes
por: Gilmore, Alyssa C, et al.
Publicado: (2022)

Remission of lupus nephritis: the trajectory of histological response in successfully treated patients
por: Malvar, Ana, et al.
Publicado: (2023)

p16(Ink4a), a marker of cellular senescence, is associated with renal disease in the B6.NZMSle1/Sle2/Sle3 mouse model of lupus
por: Tilman, Gaëlle, et al.
Publicado: (2023)

Interleukin (IL) 16: a candidate urinary biomarker for proliferative lupus nephritis
por: Häyry, Aliisa, et al.
Publicado: (2022)

Discovery of NEU1 as a candidate renal biomarker for proliferative lupus nephritis chronicity
por: Mao, Zhaomin, et al.
Publicado: (2021)

Predictors of increase in chronicity index and of kidney function impairment at repeat biopsy in lupus nephritis
por: Moroni, Gabriella, et al.
Publicado: (2022)

Performance of the 2019 EULAR/ACR systemic lupus erythematosus classification criteria in a cohort of patients with biopsy-confirmed lupus nephritis
por: Wang, Huijing, et al.
Publicado: (2021)

Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network
por: Deonaraine, Kristina K, et al.
Publicado: (2021)

Multicentre retrospective cohort study assessing the incidence of serious infections in patients with lupus nephritis, compared with non-renal systemic lupus erythematosus
por: Yates, Drew Joseph, et al.
Publicado: (2020)

Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome
por: Dall'Era, Maria, et al.
Publicado: (2015)

Urinary markers differentially associate with kidney inflammatory activity and chronicity measures in patients with lupus nephritis
por: Akhgar, Ahmad, et al.
Publicado: (2023)

Glomerular mTORC1 activation was associated with podocytes to endothelial cells communication in lupus nephritis
por: Liu, Xiaotian, et al.
Publicado: (2023)

Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial
por: Jayne, David, et al.
Publicado: (2023)

Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort
por: Cooper Blenkinsopp, Selin, et al.
Publicado: (2022)

Pathogenic autoantibodies from patients with lupus nephritis cause reduced tyrosine phosphorylation of podocyte proteins, including tubulin
por: Manson, Jessica J, et al.
Publicado: (2014)

Urinary HER2, TWEAK and VCAM-1 levels are associated with new-onset proteinuria in paediatric lupus nephritis
por: Costa-Reis, Patricia, et al.
Publicado: (2022)

Response to therapy at 6 months predicts long-term renal outcome in lupus nephritis with poor kidney function
por: Luo, Huiting, et al.
Publicado: (2022)

Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders
por: Parikh, Samir V, et al.
Publicado: (2015)

Development of a lupus nephritis suboptimal response prediction tool using renal histopathological and clinical laboratory variables at the time of diagnosis
por: Helget, Lindsay N, et al.
Publicado: (2021)

One-third of patients with lupus nephritis classified as complete responders continue to accrue progressive renal damage despite resolution of proteinuria
por: Weeding, Emma, et al.
Publicado: (2022)

A multicentre, randomised controlled study of enteric-coated mycophenolate sodium for the treatment of relapsed or resistant proliferative lupus nephritis: an Asian experience
por: Anutrakulchai, Sirirat, et al.
Publicado: (2016)

Influence of renal complications on the efficacy and adverse events of tacrolimus combination therapy in patients with systemic lupus erythematosus (SLE) during a maintenance phase: a single-centre, prospective study
por: Ishii, Sho, et al.
Publicado: (2015)

Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy
por: Parodis, Ioannis, et al.
Publicado: (2015)

Molecular signatures of intrarenal complement receptors C3AR1 and C5AR1 correlate with renal outcome in human lupus nephritis
por: Tampe, Désirée, et al.
Publicado: (2022)

Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis
por: Gatto, Mariele, et al.
Publicado: (2022)

Differential expression of IFN-α, IL-12 and BAFF on renal immune cells and its relevance to disease activity and treatment responsiveness in patients with proliferative lupus nephritis
por: Nawata, Aya, et al.
Publicado: (2023)

Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis?
por: Ugolini-Lopes, Michelle R, et al.
Publicado: (2017)

MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus NatIonwide reGistry (LUNA) coHorT
por: Sada, Kenei, et al.
Publicado: (2022)

Mer-tyrosine kinase: a novel susceptibility gene for SLE related end-stage renal disease
por: Yavuz, Sule, et al.
Publicado: (2022)

Membrane attack complex (MAC) deposition in renal tubules is associated with interstitial fibrosis and tubular atrophy: a pilot study
por: Wang, Shudan, et al.
Publicado: (2022)

Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials
por: Bruce, Ian N, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8jmrf56rhke2379932p2765lif